Packaging Repackaging - Mpje

1. Which option best describes compliance handling of expired stock during repackaging?

   Do not repackage; quarantine and remove expired product from dispensing. Expired drugs cannot be repackaged to avoid dispensing unstable products, ensuring compliance with FDA safety regulations.

2. Which patient request allows dispensing a prescription in non-child-resistant packaging?

   Patient requests non-child-resistant packaging for that prescription. PPPA allows patients to request non-child-resistant packaging for a specific prescription, overriding the default requirement for that instance only.

3. Identify the federal act that established tamper-evident packaging requirements for OTC drugs.

   Federal Anti-Tampering Act (tamper-evident OTC packaging rules). Enacted in 1983 following tampering incidents, this act requires OTC drugs to have seals indicating if packages have been compromised.

4. Which statement best describes unit-dose packaging in institutional practice?

   Packaging a single dose in a container ready for administration. Unit-dose packaging facilitates accurate dosing in institutions by providing pre-measured, labeled single doses for immediate use.

5. Which identifier must be preserved to support recalls after repackaging?

   Manufacturer lot number (and associated expiration date). Preserving the lot number ensures traceability for recalls, as required by FDA to identify and remove affected products efficiently.

6. Identify the PPPA standard definition of child-resistant packaging performance.

   Difficult for children under $5$; not difficult for normal adults. PPPA defines effective child-resistant packaging as that which 85% of children under 5 cannot open within 5 minutes, while 90% of adults can access it easily.

7. What is the key compliance risk when repackaging a drug product?

   Loss of original labeling and lot/expiration traceability. Repackaging risks compromising traceability, which is essential for recalls and ensuring patient safety under FDA regulations.

8. What is the main compliance purpose of tamper-evident packaging for OTC products?

   To provide visible evidence if the package has been opened or altered. Tamper-evident features alert consumers to potential contamination, as mandated by federal law to enhance OTC product safety.

9. What is the general rule for selecting a BUD after repackaging without stability data?

   Use the most conservative date; do not exceed manufacturer expiration. Without specific stability data, BUD must be the earliest possible date to ensure safety, never surpassing the original expiration.

10. Which type of patient request allows non-child-resistant packaging for all prescriptions?

    Patient requests a blanket waiver for all prescriptions. PPPA permits patients to provide a written blanket waiver, allowing non-child-resistant packaging for all their prescriptions indefinitely.

11. Find the correct choice: Patient has no waiver on file; which cap must be used by default?

    Child-resistant cap. Without a waiver, PPPA requires child-resistant caps to prevent access by young children in outpatient settings.

12. Which dating term is assigned after repackaging when original expiration cannot be used?

    Beyond-use date (BUD). BUD is assigned post-repackaging to indicate the date beyond which the product should not be used, based on stability considerations.

13. Which container characteristic is required when repackaging to protect product integrity?

    A suitable container with appropriate light/moisture protection and closure. Repackaging containers must mimic original protections to maintain drug stability and comply with USP and FDA standards.

14. What is repackaging in pharmacy compliance terms?

    Placing a drug from one container into another container. Repackaging involves transferring drugs to new containers, requiring adherence to FDA guidelines to preserve product integrity and traceability.

15. Find the compliance error: Repackaged tablets are labeled with drug name only and no lot link.

    Missing lot/expiration traceability to the source container. Omitting lot and expiration details violates FDA traceability rules, hindering recall processes and product safety.

16. Which prescriber instruction can require dispensing in non-child-resistant packaging?

    Prescriber specifies non-child-resistant packaging is necessary. PPPA authorizes prescribers to direct non-child-resistant packaging when deemed necessary for patient accessibility or other clinical reasons.

17. Identify the default packaging requirement when no PPPA exception is documented.

    Dispense in child-resistant packaging. Absent any documented exception or waiver, PPPA mandates child-resistant packaging to safeguard against child poisonings.

18. Identify the minimum labeling element needed to link a repackaged unit to its source.

    A traceable lot/packaging record linking unit to original container. Traceable records link repackaged units to originals, enabling effective recalls and compliance with FDA traceability requirements.

19. What is the PPPA purpose for prescription drug packaging in outpatient settings?

    To require child-resistant packaging unless an exception applies. The PPPA aims to protect children under 5 from accessing hazardous substances by enforcing special packaging standards with limited exceptions.

20. Identify the required compliance step before repackaging a drug with special storage conditions.

    Verify and maintain required storage (e.g., refrigeration, light protection). Verification ensures repackaged drugs retain efficacy under specified conditions, aligning with USP and manufacturer guidelines.

21. Which option is compliant: Prescriber writes "non-safety cap" on the prescription label directions.

    Dispense in non-child-resistant packaging and retain the prescriber instruction. Prescriber directives for non-safety caps are PPPA exceptions, requiring documentation to ensure compliant dispensing.

22. Which federal law requires child-resistant packaging for most outpatient prescriptions?

    Poison Prevention Packaging Act (PPPA). This 1970 federal law mandates child-resistant packaging for most prescription drugs to prevent accidental poisonings in young children.

23. Which action is required if a pharmacy breaks a manufacturer tamper-evident seal on an OTC drug?

    Do not sell as tamper-evident; repackage only if compliant and relabeled. Breaking the seal voids tamper-evident status, requiring repackaging to meet federal standards or removal from sale as tamper-evident.

24. Identify the compliant choice: Patient requests easy-open caps for all future prescriptions.

    Document a blanket PPPA waiver and dispense non-child-resistant as requested. Documenting a blanket waiver complies with PPPA by allowing ongoing non-child-resistant dispensing per patient preference.

25. What documentation principle is required when a patient waives child-resistant packaging?

    Maintain a record of the waiver request per policy and law. Pharmacies must document patient waivers to ensure compliance with PPPA and maintain records for potential audits or legal verification.

Study these flashcards